Cloud software for discovering cancer biomarkers and developing drugs
Official title: Topic 464 Phase I Award: Network-Based Multimodal Data Analysis Cloud Software for Cancer Biomarker Discovery and Drug Development
Funded at Sostos LLC · NIH-11191357 · Data updated 2026-11-12
This study is working on a new online tool that uses smart technology to look at different types of patient data to find new ways to treat cancer and discover helpful markers for the disease, with the goal of making cancer treatments more personalized for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sostos LLC NIH-funded |
| Lab location | 1 site (Morgantown, United States) |
| Project start | September 16, 2024 |
| Project end | September 15, 2025 |
| Funding year | 2024 |
| Award (this year) | $400,000 |
| NIH project number | 75N91024C00082-0-9999-1 |
| Project ID | NIH-11191357 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with various types of cancer, particularly those who may benefit from new biomarker discoveries and targeted therapies.
✕Less likely to help
Patients with non-cancerous conditions or those who do not have access to the cloud-based software may not receive any benefit from this research.
What this research studies
This research focuses on creating a cloud-based software platform that utilizes advanced AI technology to analyze multimodal data for cancer biomarker discovery and drug development. By modeling complex biological networks from various patient samples, the software aims to identify actionable biomarkers and potential new therapies. The project will initially test a prototype with existing cancer data to ensure usability and effectiveness, ultimately aiming to improve personalized cancer treatment options.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer diagnostics and personalized treatment strategies for patients.
How similar studies have gone: Other research has shown success with similar AI-driven approaches in biomarker discovery, indicating a promising avenue for this novel software development.
Where this research is happening
-
Sostos LLC
Morgantown, United States Active
Researchers
- Principal investigator: Ye, Qing — Sostos LLC
- Study coordinator: Ye, Qing
Related research
Other NIH-funded projects on the same topics.
-
Predicting cancer recurrence and treatment benefits for early-stage lung cancer patients
This study is working on a new test that looks at 7 specific genes to help predict if early-stage lung cancer might come back after surgery and to see if extra chemotherapy could be helpful for patients who have had surgery for stage 1 non-small cell lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.